Advanced Therapies 2021 | Developing iPSC-derived MSCs for therapeutic purposes

Miguel Forte, MD, PhD, Bone Therapeutics SA, Gosselies, Belgium, discusses the recently announced research partnership between Bone Therapeutics and Implant Therapeutics, which aims to drive the development of hypoimmunogenic induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cell (MSC)-based therapies for various indications. Dr Forte explains that the implementation of iPSC technology offers the potential to optimize the effects of current MSC-based therapies such as ALLOB, an allogeneic MSC-based cell therapy platform being investigated for bone regeneration in orthopedic indications. This interview took place at the Advanced Therapies Congress & Expo 2021.